Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Cancer Research
|
April 19, 2006
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
Hans K Erickson, Peter U Park, Wayne C Widdison, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 30, 2016
Antibody Drug Conjugates Differentiate Uptake and DNA Alkylation of Pyrrolobenzodiazepines in Tumors from Organs of Xenograft Mice
Yong Ma, S Cyrus Khojasteh, Cornelis E C A Hop, et al.
Molecular Cancer Therapeutics
|
March 13, 2012
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates
Hans K Erickson, Gail D Lewis Phillips, Douglas D Leipold, et al.
Blood
|
September 5, 2013
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies
Jutta Deckert, Peter U Park, Sharon Chicklas, et al.
Bioconjugate Chemistry
|
May 14, 2016
Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates
Jose F Ponte, Xiuxia Sun, Nicholas C Yoder, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 16, 2016
Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates
Donglu Zhang, Shang-Fan Yu, Yong Ma, et al.
Mabs
|
January 12, 2016
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates
Kalli C Catcott, Molly A McShea, Carl Uli Bialucha, et al.
Molecular Pharmaceutics
|
July 10, 2019
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation
Nicholas C Yoder, Chen Bai, Daniel Tavares, et al.
Bioconjugate Chemistry
|
September 9, 2017
Attachment Site Cysteine Thiol pK<sub>a</sub> Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates
Breanna S Vollmar, Binqing Wei, Rachana Ohri, et al.
Bioconjugate Chemistry
|
April 9, 2017
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates
Xiuxia Sun, Jose F Ponte, Nicholas C Yoder, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Cancer Research
|
April 19, 2006
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
Hans K Erickson, Peter U Park, Wayne C Widdison, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 30, 2016
Antibody Drug Conjugates Differentiate Uptake and DNA Alkylation of Pyrrolobenzodiazepines in Tumors from Organs of Xenograft Mice
Yong Ma, S Cyrus Khojasteh, Cornelis E C A Hop, et al.
Molecular Cancer Therapeutics
|
March 13, 2012
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates
Hans K Erickson, Gail D Lewis Phillips, Douglas D Leipold, et al.
Blood
|
September 5, 2013
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies
Jutta Deckert, Peter U Park, Sharon Chicklas, et al.
Bioconjugate Chemistry
|
May 14, 2016
Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates
Jose F Ponte, Xiuxia Sun, Nicholas C Yoder, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 16, 2016
Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates
Donglu Zhang, Shang-Fan Yu, Yong Ma, et al.
Mabs
|
January 12, 2016
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates
Kalli C Catcott, Molly A McShea, Carl Uli Bialucha, et al.
Molecular Pharmaceutics
|
July 10, 2019
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation
Nicholas C Yoder, Chen Bai, Daniel Tavares, et al.
Bioconjugate Chemistry
|
September 9, 2017
Attachment Site Cysteine Thiol pK<sub>a</sub> Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates
Breanna S Vollmar, Binqing Wei, Rachana Ohri, et al.
Bioconjugate Chemistry
|
April 9, 2017
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates
Xiuxia Sun, Jose F Ponte, Nicholas C Yoder, et al.
Page
of 3